Cargando…
JAK-STAT pathway inhibitors in dermatology()
The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main derma...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Sociedade Brasileira de Dermatologia
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404561/ https://www.ncbi.nlm.nih.gov/pubmed/37230920 http://dx.doi.org/10.1016/j.abd.2023.03.001 |
_version_ | 1785085325710721024 |
---|---|
author | Miot, Hélio Amante Criado, Paulo Ricardo de Castro, Caio César Silva Ianhez, Mayra Talhari, Carolina Ramos, Paulo Müller |
author_facet | Miot, Hélio Amante Criado, Paulo Ricardo de Castro, Caio César Silva Ianhez, Mayra Talhari, Carolina Ramos, Paulo Müller |
author_sort | Miot, Hélio Amante |
collection | PubMed |
description | The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main dermatological targets of JAK-STAT pathway inhibitors are inflammatory or autoimmune diseases such as psoriasis, vitiligo, atopic dermatitis and alopecia areata; however, several dermatoses are under investigation to expand this list of indications. As JAK-STAT pathway inhibitors should gradually occupy a relevant space in dermatological prescriptions, this review presents the main available drugs, their immunological effects, and their pharmacological characteristics, related to clinical efficacy and safety, aiming to validate the best dermatological practice. |
format | Online Article Text |
id | pubmed-10404561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Sociedade Brasileira de Dermatologia |
record_format | MEDLINE/PubMed |
spelling | pubmed-104045612023-08-08 JAK-STAT pathway inhibitors in dermatology() Miot, Hélio Amante Criado, Paulo Ricardo de Castro, Caio César Silva Ianhez, Mayra Talhari, Carolina Ramos, Paulo Müller An Bras Dermatol Review The JAK-STAT signaling pathway mediates important cellular processes such as immune response, carcinogenesis, cell differentiation, division and death. Therefore, drugs that interfere with different JAK-STAT signaling patterns have potential indications for various medical conditions. The main dermatological targets of JAK-STAT pathway inhibitors are inflammatory or autoimmune diseases such as psoriasis, vitiligo, atopic dermatitis and alopecia areata; however, several dermatoses are under investigation to expand this list of indications. As JAK-STAT pathway inhibitors should gradually occupy a relevant space in dermatological prescriptions, this review presents the main available drugs, their immunological effects, and their pharmacological characteristics, related to clinical efficacy and safety, aiming to validate the best dermatological practice. Sociedade Brasileira de Dermatologia 2023 2023-05-23 /pmc/articles/PMC10404561/ /pubmed/37230920 http://dx.doi.org/10.1016/j.abd.2023.03.001 Text en © 2023 Sociedade Brasileira de Dermatologia. Published by Elsevier España, S.L.U. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Miot, Hélio Amante Criado, Paulo Ricardo de Castro, Caio César Silva Ianhez, Mayra Talhari, Carolina Ramos, Paulo Müller JAK-STAT pathway inhibitors in dermatology() |
title | JAK-STAT pathway inhibitors in dermatology() |
title_full | JAK-STAT pathway inhibitors in dermatology() |
title_fullStr | JAK-STAT pathway inhibitors in dermatology() |
title_full_unstemmed | JAK-STAT pathway inhibitors in dermatology() |
title_short | JAK-STAT pathway inhibitors in dermatology() |
title_sort | jak-stat pathway inhibitors in dermatology() |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404561/ https://www.ncbi.nlm.nih.gov/pubmed/37230920 http://dx.doi.org/10.1016/j.abd.2023.03.001 |
work_keys_str_mv | AT miothelioamante jakstatpathwayinhibitorsindermatology AT criadopauloricardo jakstatpathwayinhibitorsindermatology AT decastrocaiocesarsilva jakstatpathwayinhibitorsindermatology AT ianhezmayra jakstatpathwayinhibitorsindermatology AT talharicarolina jakstatpathwayinhibitorsindermatology AT ramospaulomuller jakstatpathwayinhibitorsindermatology |